ATE435211T1 - Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus - Google Patents

Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus

Info

Publication number
ATE435211T1
ATE435211T1 AT01961676T AT01961676T ATE435211T1 AT E435211 T1 ATE435211 T1 AT E435211T1 AT 01961676 T AT01961676 T AT 01961676T AT 01961676 T AT01961676 T AT 01961676T AT E435211 T1 ATE435211 T1 AT E435211T1
Authority
AT
Austria
Prior art keywords
imidazolidinone
hepatitis
virus
protease inhibitors
serine protease
Prior art date
Application number
AT01961676T
Other languages
English (en)
Inventor
Ashok Arasappan
Tejal Parekh
F Njoroge
Viyyoor Girijavallabhan
Ashit Ganguily
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE435211T1 publication Critical patent/ATE435211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT01961676T 2000-07-21 2001-07-19 Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus ATE435211T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22011000P 2000-07-21 2000-07-21
PCT/US2001/022828 WO2002008198A2 (en) 2000-07-21 2001-07-19 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
ATE435211T1 true ATE435211T1 (de) 2009-07-15

Family

ID=22822106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01961676T ATE435211T1 (de) 2000-07-21 2001-07-19 Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus

Country Status (10)

Country Link
US (1) US6838475B2 (de)
EP (1) EP1301486B1 (de)
JP (1) JP2004515464A (de)
AR (1) AR034127A1 (de)
AT (1) ATE435211T1 (de)
AU (1) AU2001282922A1 (de)
CA (1) CA2410766A1 (de)
DE (1) DE60139127D1 (de)
ES (1) ES2327819T3 (de)
WO (1) WO2002008198A2 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169880T3 (es) 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
DE60329367D1 (de) 2002-01-23 2009-11-05 Schering Corp Verwendung bei der bekämpfung von hepatitis c virusinfektion
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
JP2005526102A (ja) 2002-04-01 2005-09-02 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスｒｎａ依存性ｒｎａポリメラーゼのピラノンおよびピランジオン阻害剤
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
CN104163841B (zh) 2002-06-28 2016-08-24 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
EP1408031A1 (de) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidinderivate zur Behandlung von Hepatitis C Virusinfektion
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DK1654261T3 (da) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C-inhibitorforbindelser
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
PL1658302T3 (pl) 2003-07-25 2011-03-31 Idenix Pharmaceuticals Inc Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
JP4527722B2 (ja) 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
WO2005028501A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
KR20060085248A (ko) 2003-09-26 2006-07-26 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (de) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Kombinationen für die HCV-Behandlung
JP2007532479A (ja) 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
PL1713823T3 (pl) 2004-01-30 2010-04-30 Medivir Ab Inhibitory proteazy serynowej NS-3 HCV
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
SI1719773T1 (sl) 2004-02-24 2009-08-31 Japan Tobacco Inc Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
CN1946692A (zh) 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的3,4－(环戊基)－稠合的脯氨酸化合物
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
TW200529823A (en) 2004-02-27 2005-09-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
KR20060124725A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 프로테아제의 억제제
CA2566610A1 (en) 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006026352A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
US7425640B2 (en) 2004-10-29 2008-09-16 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
PE20070011A1 (es) * 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
ME01318B (me) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PL1913015T3 (pl) 2005-07-29 2014-04-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
SI2194043T1 (sl) * 2005-08-19 2014-04-30 Vertex Pharmaceuticals Incorporated Postopki
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (de) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis-C-Virusvarianten
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2340836A1 (de) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-kristalle enthaltend VX-950 und deren pharmazeutische Zusammensetzungen
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (de) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
MX2009006880A (es) 2006-12-22 2009-07-03 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
EP2134717A2 (de) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Serinprotease-hemmer
AR065498A1 (es) * 2007-02-27 2009-06-10 Vertex Pharma Co- critales de vx-950 (un inhibidor del virus de la hepatitis c) y composiciones farmaceuticas que los comprenden
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
DK2144604T3 (da) * 2007-02-28 2011-10-17 Conatus Pharmaceuticals Inc Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
DE102007032836A1 (de) 2007-07-12 2009-01-15 Evonik Röhm Gmbh Emulsionspolymerisat enthaltend Aktivatoren, Verfahren zu dessen Herstellung sowie dessen Verwendung in Zwei- oder Mehrkomponentensystemen
EP2188274A4 (de) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Virale polymerasehemmer
EP2408761B1 (de) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituierte indolderivate und verwendungsverfahren dafür
AR068107A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
MX2010002318A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
CA2704284A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
TW200936131A (en) * 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
EP2307434B1 (de) 2008-07-02 2014-02-12 IDENIX Pharmaceuticals, Inc. Verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326628A1 (de) 2008-08-20 2011-06-01 Schering Corporation Azo-substituierte pyridin- und pyrimidinderivate und ihre verwendung bei der behandlung viraler infektionen
AR072939A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
EP2435424B1 (de) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Aus drei miteinander verbundenen aryleinheiten zusammengesetzte antivirale verbindungen zur behandlung von krankheiten wie hepatitis c
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2536410B1 (de) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituierte pyrimidinderivate und ihre verwendung bei der behandlung viraler infektionen
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
PE20130151A1 (es) 2010-03-31 2013-02-21 Gilead Pharmasset Llc Sintesis estereoselectiva de activos que contienen fosforo
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (de) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Kondensierte tetrazyklische derivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852604B1 (de) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
MD20150036A2 (ro) 2012-10-08 2015-08-31 Idenix Pharmaceuticals, Inc. Analogi de 2'-cloro nucleozide pentru tratarea hepatitei virale C
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
EP2920195A1 (de) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alaninester eines rp-nukleosidanalogons
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2921160C (en) 2013-08-27 2021-04-13 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (de) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
EP3083654A1 (de) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or-nukleoside zur behandlung von hcv
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066795A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169880T3 (es) * 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
WO1999050230A1 (en) * 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
KR20010106444A (ko) * 1998-08-17 2001-11-29 존 더블류. 갈루치 2세 알파-케토 헤테로사이클을 포함하는 세린 프로테아제 억제제
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
AU2001282922A1 (en) 2002-02-05
CA2410766A1 (en) 2002-01-31
JP2004515464A (ja) 2004-05-27
DE60139127D1 (de) 2009-08-13
ES2327819T3 (es) 2009-11-04
EP1301486A2 (de) 2003-04-16
EP1301486B1 (de) 2009-07-01
US20020102235A1 (en) 2002-08-01
AR034127A1 (es) 2004-02-04
WO2002008198A2 (en) 2002-01-31
WO2002008198A3 (en) 2002-07-18
US6838475B2 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
ATE435211T1 (de) Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus
CY2011020I1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
DE60135087D1 (de) Dipeptidnitrile als inhibitoren von cathepsin k
DE60138567D1 (de) Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
DK0932617T3 (da) Inhibitorer af serinproteaser, især af hepatitis C-virus-NS3-protease
AU8063701A (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
DE60221875D1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
DE60332814D1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
ATE506104T1 (de) Hepatitis-c-virus-hemmer
ATE443703T1 (de) Prolinderivate als ns3-serine protease hemmer, zur verwendung bei der bekämpfung von hepatitis c virusinfektion
ATE244235T1 (de) Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
DE60210612D1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE260274T1 (de) Furanonderivate als inhibitoren von cathepsin s
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
DE50115086D1 (de) Lösungen von UV-vernetzbaren Polyacrylaten
DK1268519T3 (da) Inhibitorer af serinproteaser, især hepatitis C-virus NS3-protease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties